These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 15000418)

  • 21. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review of rivastigmine: a reversible cholinesterase inhibitor.
    Williams BR; Nazarians A; Gill MA
    Clin Ther; 2003 Jun; 25(6):1634-53. PubMed ID: 12860489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based pharmacotherapy of Alzheimer's disease.
    Evans JG; Wilcock G; Birks J
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
    Blesa R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease.
    Davis KL; Marin DB; Kane R; Patrick D; Peskind ER; Raskind MA; Puder KL
    Int J Geriatr Psychiatry; 1997 Oct; 12(10):978-88. PubMed ID: 9395929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine in Alzheimer disease: efficacy over two years.
    Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
    Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
    Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
    Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study.
    de Silva HA; Pathmeswaran A; Gunatilake SB
    Ceylon Med J; 2005 Sep; 50(3):106-9. PubMed ID: 16252573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
    Forette F; Anand R; Gharabawi G
    Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivastigmine. A review of its use in Alzheimer's disease.
    Spencer CM; Noble S
    Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan.
    Ashizawa T; Igarashi A; Sakata Y; Azuma M; Fujimoto K; Kobayashi T; Takase Y; Ikeda S
    J Alzheimers Dis; 2021; 81(1):367-374. PubMed ID: 33780368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
    Gauthier S; Juby A; Rehel B; Schecter R
    Int J Clin Pract; 2007 Jun; 61(6):886-95. PubMed ID: 17504350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
    Gauthier S; Juby A; Morelli L; Rehel B; Schecter R;
    Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.